Latest Multiple myeloma Stories
ATLANTA, Dec. 11, 2012 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: PCYC) today announced follow-up findings from an ongoing, open-label, Phase 2, single-agent study suggesting that in patients with relapsed or refractory mantle cell lymphoma (MCL), both those who were bortezomib-naive and bortezomib-exposed, the investigational oral agent ibrutinib (PCI-32765) resulted in high and durable responses and was generally well tolerated. In the study, 111 patients received ibrutinib and...
ATLANTA, Dec. 11, 2012 /PRNewswire/ -- Janssen Research & Development, LLC, today announced follow-up findings from an ongoing, open-label, Phase 2, single-agent study showing that in patients with relapsed or refractory mantle cell lymphoma (MCL), the investigational oral agent ibrutinib (PCI-32765) resulted in an overall response rate (ORR) of 68 percent, including a complete response (CR) of 22 percent and a partial response (PR) of 46 percent. The study included both...
BOULDER, Colo., Dec. 10, 2012 /PRNewswire/ -- Array BioPharma Inc. (NASDAQ: ARRY) today announced positive data for ARRY-520 and ARRY?614 at the 2012 Annual Meeting of the American Society of Hematology (ASH) in Atlanta, Georgia. (Logo: http://photos.prnewswire.com/prnh/20121029/LA02195LOGO) New results presented at the meeting for ARRY-520 in addition to those described in the abstracts published by ASH in early November included: Overall survival of 19 months and...
Encouraging safety and efficacy data on novel and emerging therapies presented at the 54th Annual Meeting of the American Society of Hematology (ASH) signal an important step forward in the development of treatment strategies for patients with hard-to-treat leukemia, myeloma, and myelofibrosis. Ongoing discoveries of critical molecular markers, pathways, and other drivers of some of the most difficult-to-treat forms of blood cancer have provided unprecedented opportunities for the...
ATLANTA, Dec. 9, 2012 /PRNewswire-USNewswire/ -- Encouraging safety and efficacy data on novel and emerging therapies presented at the 54th Annual Meeting of the American Society of Hematology (ASH) signal an important step forward in the development of treatment strategies for patients with hard-to-treat leukemia, myeloma, and myelofibrosis. Ongoing discoveries of critical molecular markers, pathways, and other drivers of some of the most difficult-to-treat forms of blood cancer...
Mitchell Vazquez, owner of the GCI Financial, makes noble use of his financial success by donating substantial gifts to Multiple Myeloma Research Foundation. This organization is dedicated to finding cures and treatments for certain types of cancer. He supports this cause and helps them make advances in bringing new treatments to patients and extending their lives. New York (PRWEB) December 06, 2012 Mitchell Vazquez, owner of the GCI Financial, makes noble use of his financial success by...
SOUTH SAN FRANCISCO, Calif., Dec. 6, 2012 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced the launch of the Make Your Mark at the Multiple Myeloma Experience at the 54(th) American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta, Georgia on December 8, 2012. The experience is designed to celebrate progress made in the treatment of multiple myeloma, an incurable blood cancer, and encourage members of the multiple myeloma community to...
BUFFALO, N.Y., Nov. 29, 2012 /PRNewswire/ -- Empire Genomics announced today it has acquired an exclusive license for patent pending novel genomic biomarkers from Emory University for use in developing a molecular diagnostic test that could help satisfy a large unmet medical need in determining ideal therapeutic treatment for multiple myeloma patients. Recent data point to certain genetic biomarkers that may identify which patients would benefit from receiving treatment with the...
QUÉBEC CITY, Nov. 19, 2012 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that perifosine, its oral AKT inhibitor, combined with temsirolimus ("TEM"), was well tolerated in an investigator driven Phase 1 clinical trial in recurrent or progressive malignant glioma ("MG"). Data were presented over the weekend by Thomas J. Kaley, MD, Director, Neuro-Oncology Fellowship Program at Memorial Sloan-Kettering Cancer Center, during a...
CAMBRIDGE, Mass., BOSTON and NEW YORK, Nov. 8, 2012 /PRNewswire/ -- GNS Healthcare, Inc. (GNS), the leading healthcare data analytics company focused on enabling personalized medicine to improve human health, today announced that it has entered into a collaboration with Dana-Farber Cancer Institute (Dana-Farber) and Mount Sinai School of Medicine (Mount Sinai) to create a data-driven computer model of multiple myeloma, the second most common blood cancer in the U.S. that constitutes...
